The early revenue generation and rapid payer adoption of KOMZIFTI suggest strong commercial viability. With multiple clinical data readouts expected in 2026 and a well-funded runway into 2028, traders should monitor upcoming data from KOMET-007 (1H 2026) and the progression of Phase 3 frontline trials as key value inflection points.
Price Chart
Executive Summary
Kura Oncology reported Q4 and full-year 2025 financial results, highlighted by $2.1 million in net product revenue from the initial five weeks of KOMZIFTI™ (ziftomenib) commercial sales following its November 13 FDA approval for R/R NPM1-mutated AML. The company emphasized strong early commercial momentum, rapid payer coverage, and a robust cash position of $667.2 million, which—combined with $180 million in anticipated collaboration payments—is expected to fund operations into Q4 2027 and advance ziftomenib to Phase 3 topline data in frontline AML by 2028.
Key Financial Metrics
Key Facts
- Generated $2.1 million in net product revenue from KOMZIFTI in first five weeks post-FDA approval (Nov 13–Dec 31, 2025)
- Received $135 million milestone payment from Kyowa Kirin upon product delivery within five days of approval
- Cash, cash equivalents, and short-term investments totaled $667.2 million as of December 31, 2025
- Anticipated $180 million in future collaboration payments from Kyowa Kirin to support development through Phase 3 AML data
- Net loss widened to $81.0 million in Q4 2025 vs. $19.2 million in Q4 2024 due to increased R&D and SG&A expenses tied to commercialization
- Initiated pivotal Phase 3 KOMET-017 trials in frontline AML, triggering two $30 million milestone payments from Kyowa Kirin
Financial Impact
$2.1 million in net product revenue in first partial quarter; $15.2 million collaboration revenue in Q4; total cash resources (~$847M with expected milestones) sufficient to fund through key 2028 Phase 3 readout
Risk Factors
- Differentiation syndrome observed in 26% of patients, including fatal cases, which may limit use or require risk mitigation
- Widening net loss ($81M in Q4) driven by rising R&D and commercialization costs
- Future collaboration payments from Kyowa Kirin are contingent on milestones and not guaranteed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249967 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 8-K | $12.09 $11.37 | ▼ −6.00% | ▼ −5.66% | $10.65 (−11.91%) |
Sep 8, 2026 24d ago | 8-K | $12.52 $11.30 | ▼ −9.74% | ▼ −8.63% | $10.65 (−14.94%) |
Aug 24, 2026 5w ago | Insider Cluster | $12.40 $12.65 | ▲ +2.02% | ▲ +1.55% | $10.65 (−14.11%) |
Aug 21, 2026 6w ago | Insider Cluster | $11.89 $12.66 | ▲ +6.48% | ▲ +6.00% | $10.65 (−10.43%) |
Aug 17, 2026 6w ago | Insider Buy | $12.33 $13.59 | ▲ +10.22% | ▲ +10.42% | $10.65 (−13.63%) |
Aug 12, 2026 7w ago | Press Release | $10.09 $11.71 | ▲ +16.06% | ▲ +18.02% | $10.65 (+5.55%) |
Aug 5, 2026 8w ago | Press Release | $9.20 $9.94 | ▲ +8.04% | ▲ +7.69% | $10.65 (+15.76%) |
Jul 29, 2026 9w ago | 8-K | $9.31 $9.28 | ▼ −0.32% | ▼ −3.94% | $10.65 (+14.39%) |
Jul 14, 2026 11w ago | Press Release | $11.24 $10.68 | ▼ −4.98% | ▼ −3.69% | $10.65 (−5.25%) |
Jun 3, 2026 17w ago | Press Release | $8.66 $8.68 | ▲ +0.29% | ▲ +4.11% | $10.65 (+23.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access